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Abstract 
Objective: Non-steroidal anti-inflammatory drugs (NSAIDs) are the most commonly prescribed pain 
control medications following periodontal surgery. This study aimed to compare the efficacy of three 
drug regimens namely celecoxib, celecoxib + caffeine and ibuprofen for pain relief following crown 
lengthening surgery. 
Methods: This randomized, double blind clinical trial was performed on 45 patients aged 20-60 
years requiring crown lengthening of maxillary teeth. The subjects were randomly divided into three 
groups (n=15) receiving ibuprofen (400mg), celecoxib (200mg) and celecoxib (200mg) + caffeine 
(30mg). Each patient took one dose of the respective medications 30 minutes prior to surgery. Other 
doses were prescribed 1, 8, 16 and 24 hours after surgery. Pain scores were recorded using visual 
analog scale (VAS) at 1, 2, 4, 8, 16, 24 and 48 hours post operation. 
Results: The mean VAS scores were significantly lower in celecoxib + caffeine group than in 
celecoxib group at 1 and 2 hours after surgery (H1: 2.33 (1.95) vs. 4.47 (2.56), p=0.026) (H2: 2.47 
(1.60) vs. 4.80 (2.40), p=0.009). The pain scores were significantly lower in celecoxib + caffeine 
group than ibuprofen group at 8, 16 and 24 hours after the procedure (H8: 1.80 (1.21) vs. 3.73 
(1.94), p=0.012) (H16: 1.07 (1.03) vs. 2.73 (1.87), p=0.012) (H24: 0.47 (0.64) vs. 1.87 (1.25), 
p=0.004). No significant difference was found in analgesic efficacy of celecoxib and ibuprofen. 
Conclusion: The combination of celecoxib + caffeine showed higher efficacy than other medications 
for pain control following crown lengthening surgery. Caffeine may enhance the analgesic effect of 
celecoxib. 
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Pain following periodontal surgery is a common 
occurrence. In a study by Canakci, post- 
operative pain was reported by 79% of patients 
following open flap debridement surgery, 89% 
of patients after gingivectomy, and 93% 
following open flap surgery with osseous 
resection (1). Many factors may affect the 
severity of pain such as the patient age,  duration 
of surgery, type of surgical procedure, surgical 
site, extent of incision, and psychological factors 
like stress and anxiety (2-4). Many inflammatory 
mediators such as prostaglandins, leukotrienes, 
interleukins, histamines and bradykinin are 
released following injury or trauma to the 
periodontal tissues (2, 5). 
Post-operative pain management plays an 
important role in patient satisfaction and 
continuation  of  treatment  process  (6). NSAIDs 




are among the most commonly prescribed drugs 
for pain control following periodontal  surgery 
(7, 8). NSAIDs inhibit the cyclooxygenase 
(COX) enzyme, prevent the synthesis of 
prostaglandins and consequently decrease pain 
(9). Two isoforms of COX enzyme are found in 
the body namely COX1 and COX2 (2). 
Celecoxib is a new generation of NSAIDs     that 
selectively inhibits COX2 enzyme (10-13). It is 
commonly used for treatment of rheumatoid 
arthritis, osteoarthritis, acute pain and 
dysmenorrhea in adults (2, 14). It has analgesic, 
antipyretic, and anti-inflammatory effects. It 
does not have gastrointestinal complications or 
platelet disorders that are among the 
complications of conventional NASAIDs (13). 
Due to optimal properties such as long plasma 
half-life of 11 hours compared to that of 
conventional NSAIDs (4-6 hours) and  also 
longer dosing interval compared to NSAIDs, 
patients are more comfortable taking celecoxib 
(15, 16). 
An effective strategy for more efficient pain 
relief is to combine different analgesics to 
enhance their efficacy and decrease side effects 
by reducing their dosage (17). In this process, it 
is important to find new drug formulations and 
combinations for more efficient pain control. 
Caffeine is an alkaloid central nervous system 
stimulant from the family of methylxanthines 
used in conjunction with opioid and non-opioid 
analgesics to enhance their efficacy (18). It does 
not have a specific effect per se; but,it enhances 
the efficacy of analgesics when used in 
combination with them (17). According to a 
study by Derry, et al. (2012) caffeine in 
conjunction with analgesics increased their 
efficacy and resulted in more efficient pain relief 
of patients (19). The most commonly consumed 
sources of caffeine include coffee, tea, chocolate 
and soda (soft drinks) (19, 20). 
Considering the boosting effect of caffeine in 
conjunction with analgesics and limited studies 
on the efficacy of celecoxib in combination with 
 
caffeine, this study aimed to compare the 
efficacy of three drug regimens namely 
celecoxib, celecoxib + caffeine and  ibuprofen 





This double blind clinical trial was conducted on 
45 patients aged 20-60 years selected among 
those presenting to the Periodontology 
Department of Babol University of Medical 
Sciences, School of Dentistry for crown 
lengthening surgery. The study proposal was 
approved by the Ethics Committee of the 
university and patients signed written informed 
consent forms thoroughly explaining the steps of 
the study. This study was registered in  IRCT 
(ID: IRCT201305253813N2). The inclusion 
criteria were no history of systemic disease, no 
allergy to NSAIDs, age range of 20-60 years, 
taking no pain medications for 48 hours prior to 
taking the understudy drugs, and being able to 
read, comprehend and fill out the questionnaire. 
The exclusion criteria were pregnancy or 
nursing, gastrointestinal diseases such as peptic 
ulcer, history of periodontal surgery in the past 6 
months and phobia of dental procedures. 
The understudy drugs namely 200mg celecoxib 
(Sajjad Darou, Tehran, Iran), 400mg ibuprofen 
(Hakim Pharmaceuticals, Tehran, Iran) and 
caffeine (Merck, Germany) were obtained. The 
drugs were poured into uniform capsules in 
separate packs and coded for the understudy 
groups by a pharmacologist. As such, three 
groups of drugs, 15 each, with different codes 
were prepared. The three groups included 
celecoxib with caffeine, celecoxib without 
caffeine and ibuprofen. 
Qualified subjects were entered in the study after 
filling out the questionnaire and signing  a 
written informed consent form. Subjects were 
selected using sequential simple random 
sampling   (13,   15).   The   three   codes     were 




randomly written on pieces of paper 
corresponding to the total number of subjects 
(three groups of 15 of the three codes yielding a 
total of 45 cards) and patients randomly received 
a piece of paper indicating their group  
allocation. Patients underwent crown  
lengthening by residents of periodontics who  
had almost equal level of expertise. Patient 
allocation to residents was matched. The 
understudy subjects were 45 patients in three 
groups of 15. Each group received their assigned 
drugs. In order to match the groups and  
minimize bias in results and also to eliminate the 
possible confounders in surgery at different sites 
of the oral cavity, only patients who required 
crown lengthening of the maxillary teeth were 
selected. 
Taking the medications: A dose of the respective 
medication was prescribed for each patient half 
an hour prior to surgery and then at 1, 8, 16 and 
24 hours post-treatment. 
Patients were provided with VAS, in the form of 
a ruler with 10cm length. The leftmost point 
indicated complete analgesia and the rightmost 
point indicated the highest level of pain 
imaginable. Patients expressed their level of pain 
 
by marking a point somewhere in-between the 
two endpoints. The results of changes in VAS 
score at 1, 2, 4, 8, 16, 24 and 48 hours post- 
operation were recorded in the respective forms. 
For ethical purposes, acetaminophen codeine  
was prescribed for all patients as a 
supplementary analgesic. The patients were 
instructed to use it only if they experienced 
intolerable pain and if so, record their consumed 
dosage, time of consumption and number of pills 
taken. 
Data were analyzed using SPSS version 18. 
Descriptive statistics, repeated measures 
ANOVA and Tukey’s post-hoc test were applied 




This study evaluated 45 patients including 28 
females (62.2%) and 17 males (37.7%) with a 
mean age of 33.66 (8.47) years (range 20-60 
years). Patients were evaluated in three groups 
of 15 and surgeries were only performed on the 
maxilla. The mean pain score in the understudy 
groups based on VAS at 1, 2, 4, 8, 16, 24 and 48 
hours after crown lengthening was calculated. 
 













Comparison of intra- and inter-group data using 
repeated measures ANOVA revealed a 
significant reduction in the severity of pain over 
time (p<0.0001 and p=0.009, respectively). 
The results of Tukey’s post hoc test revealed that 
at 1 and 2 hours post-surgery, the mean VAS 
score in the celecoxib + caffeine group was 
significantly lower than that in the celecoxib 
group (H1: 2.33 (1.95) vs. 4.47 (2.56),  p=0.026) 
(H2: 2.47 (1.60) vs. 4.80 (2.40), p=0.009).    The 
pain scores were significantly lower in celecoxib 
+ caffeine group than in ibuprofen group at 8, 16 
Group 1 hour 2 hours 4 hours 8 hours 16 hours 24 hours 48 hours 
400mg 
3.13 (1.92) 3.13 (2.10) 3.27 (1.75) 3.73 (1.94) 2.73 (1.87) 1.87 (1.25) 1.20 (1.86) 
Ibuprofen 
Max= 7
 Max= 7 Max= 7 Max= 6 Max= 5 Max= 4 Max= 5 
Min= 0 Min= 0 Min= 1 Min= 0 Min= 0 Min= 0 Min= 0 
200mg 
2.33 (1.95) 2.47 (1.60) 2.53 (1.64) 1.80 (1.21) 1.07 (1.03) 0.47 (0.64) 0.20 (0.41) 
Celecoxib 
Max= 8
 Max= 7 Max= 6 Max= 3 Max= 3 Max= 2 Max= 1 
+ 30mg 
Min= 0
 Min= 1 Min= 0 Min= 0 Min= 0 Min= 0 Min= 0 
200mg 
4.47 (2.56) 4.80 (2.40) 3.60 (2.06) 2.87 (2.00) 1.40 (1.55) 1.00 (1.36) 0.53 (1.06) 
Celecoxib 
Max= 9
 Max= 9 Max= 8 Max= 8 Max= 6 Max= 5 Max= 4 
Min= 2 Min= 2 Min= 1 Min= 0 Min= 0 Min= 0 Min= 0 
 




and 24 hours after the procedure (H8: 1.80  
(1.21)   vs.   3.73   (1.94),  p=0.012)   (H16: 1.07 
 
(1.03)   vs.   2.73   (1.87),  p=0.012)   (H24: 0.47 




















0 8 16 24 32 40 48 56 
Time (h) 
Diagram 1- Comparison of the mean pain score in the three groups at different time pointsfollowing crown 
lengthening 
 
No significant difference was found in analgesic 
efficacy of celecoxib and ibuprofen. 
No significant difference was noted in degree of 
pain among the understudy time points in males 
while in females, at 2 hours post-surgery, the 
mean VAS score in the celecoxib + caffeine 
group was significantly lower than that in the 
celecoxib group (p=0.015). This value in the 
ibuprofen group was lower than that in the 
celecoxib group (p=0.047). At 4 hours, the mean 
VAS in the celecoxib + caffeine group was 
significantly lower than that in the celecoxib 
group (p=0.011). At 8 hours, the mean VAS 
score in the celecoxib + caffeine group was 
significantly lower than that in the celecoxib 
(p=0.027) and ibuprofen (p=0.006) groups. At  
16 hours, the mean VAS score in the celecoxib + 
caffeine group was significantly lower than that 
in the ibuprofen group (p=0.011). At 24 hours, 
the mean VAS score in the celecoxib + caffeine 
group was significantly lower than that in the 
ibuprofen group (p=0.007). No other differences 
were noted in the mean VAS score in females. 
Comparison of the three groups in terms of   age 
range at different time points using ANOVA and 
post-hoc Tukey’s test revealed the followings: 
In those aged ≤30 years: Significant differences 
were noted among the three groups at 24 
(p=0.026) and 48 (p=0.044) hours post-surgery. 
At 24 hours, the mean VAS score in the 
celecoxib + caffeine group was significantly 
lower than that in the ibuprofen group  (H24: 
0.38 (0.7) vs. 2 (1.6), p=0.03). At 48 hours, the 
mean VAS score in the celecoxib + caffeine 
group was significantly lower than that in the 
ibuprofen group (H48: 0.13 (0.35) vs. 1.83 (2.1), 
p=0.046). 
In those aged >30 years: Comparison of the 
three groups at 1 (p=0.038), 2 (p=0.019) and 8 
(p=0.033) hours post-surgery  revealed 
significant differences in the mean pain score. At 
1 hour post-surgery, the mean VAS score in the 
celecoxib + caffeine group was significantly 
lower than that in the celecoxib group (H1: 
2.29±2.8 vs. 5.22±2.5, p=0.047). At 2 hours,  the 
mean VAS score in the ibuprofen group was 
significantly lower than that in the celecoxib 












mean VAS score in the celecoxib + caffeine 
group was significantly lower than that in the 
celecoxib group (H2: 2.71 (2.13) vs. 5.33 (2.2), 
p=0.034). At 8 hours, the mean VAS score in the 
celecoxib + caffeine group was significantly 
lower than that in the ibuprofen group (H8: 1.71 




Periodontal surgery is often associated with  
pain, swelling and local inflammation of the 
tissue. Thus, a proper choice of analgesic and 
anti-inflammatory drugs with adequate efficacy 
and minimal side effects is particularly  
important for both the clinicians and patients (5). 
Previous studies have demonstrated that  
selective COX2 inhibitors like celecoxib 
significantly decrease the inflammatory cell 
count, edema and vascular dilation following 
inflammation. Decreased inflammation and 
inflammatory cell count result in less release of 
pain mediators and thus, these drugs can 
significantly decrease pain in the first hours 
following tissue injury (8). Ibuprofen is more 
effective than celecoxib but has more side  
effects as well. However, the side effects of 
ibuprofen are less than those of other NSAIDs 
(21). Celecoxib is among the first COX2 
inhibitors with side effects less than those of 
ibuprofen (22). 
Cheung, et al. in 2007 concluded that celecoxib 
was more effective in decreasing post-operative 
pain than ibuprofen. However, in our study, 
celecoxib and ibuprofen had similar efficacy. 
This may be due to the use of 400mg dose of 
celecoxib, which is twice the dose used in their 
study (16). 
Insignificant difference between the analgesic 
efficacy of celecoxib and ibuprofen in our study 
is similar to the finding of Salo et al. in 2003. 
They compared the analgesic efficacy of 
celecoxib and ibuprofen in trauma patients in an 
emergency   ward   (23).   The   results   of  other 
 
studies also indicated no significant difference in 
efficacy of celecoxib and ibuprofen (13, 22). 
Another study showed equal efficacy of 
ibuprofen and celecoxib in decreasing 
periodontal pain; which is similar to our finding. 
Thus, considering the side effects of ibuprofen 
and also longer dosing interval of celecoxib (2 
times daily for celecoxib versus 4 times daily for 
ibuprofen), celecoxib should be preferably used 
for pain control (15). 
In the current study, caffeine enhanced the 
analgesic efficacy of celecoxib. Previous studies 
demonstrated that caffeine increased the 
analgesic and anti-inflammatory effect of 
celecoxib (3, 24, 25). McQuay et al. in 1996 
demonstrated that ibuprofen in conjunction with 
caffeine had greater analgesic efficacy for use 
after third molar surgery compared to ibuprofen 
alone (26). 
Diamond et al. in 2000 concluded that 
combination of ibuprofen and caffeine had 
greater analgesic efficacy for neural headaches 
compared to ibuprofen, attributed to the 
analgesic potential of caffeine enhancing the 
analgesic effect of ibuprofen (27). 
A study on rats showed that combination of 
caffeine and acetylsalicylic acid may decrease 
the drug side effects and enhance the analgesic 
efficacy (17). Another study showed significant 
analgesic effect of caffeine in combination with 
opioids (28). Our finding regarding the boosting 
effect of caffeine is in line with the results of 
afore mentioned studies. 
In terms of age range, since the patients were in 
the age range of 20-60 years, patients were 
matched in terms of age in the three groups. On 
the other hand, in each group, subjects were 
divided into two subgroups of ≤30 and >30  
years and then data were analyzed. The results 
showed that in patients ≤30 years, significant 
differences were noted in the mean pain score 
between celecoxib + caffeine and ibuprofen at  
24 and 48 hours in favor of the former regimen. 
In  those  >30  years,  at  1,  2  and  8  hours,  the 




difference in pain score between the celecoxib 
and celecoxib + caffeine groups was significant 
in favor of the latter regimen. Difference in pain 
at early hours post-operation in older age group 
indicates the lower pain threshold of older 
patients and the need for prescribing an  
analgesic with rapid absorption. Caffeine can 
accelerate the absorption of celecoxib and this 
may explain the obtained results. 
In terms of gender, no significant difference was 
noted at any time point in males. However, 
significant differences might have been found if 
there had been a larger sample size. 
The analgesic effect of caffeine is attributed to 
several factors such as the presence of caffeine  
in combination with analgesics and enhancing 
their efficacy by inhibiting the adenosine 
receptors and subsequently the synthesis of 
COX2 enzyme and also its effects on the central 
nervous system leading to increased 
consciousness, and decreased pain and fatigue 
(3, 18, 28, 29). 
In the current study, the highest pain reduction 
was seen in celecoxib + caffeine group. Such 
significant difference may be due to the caffeine 
pharmacokinetics because it inhibits 
phosphodiesterase enzyme and increases 
intracellular cAMP and subsequently increases 
the secretion of stomach acid and peristalsis  and 
 
consequently, it acceleratesdrug absorption. The 
drug reaches the target organ and exerts its effect 




In long-term, celecoxib has less gastrointestinal 
side effects than ibuprofen. Also, it has 
longerdosing interval than ibuprofen(twice daily 
versus 4 times daily) making its use more 
convenient for patients. Caffeine enhanced the 
analgesic efficacy of celecoxib. Thus,  to 
decrease dosage and avoid the side effects of 
other analgesics, celecoxib + caffeine is 
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